Brazil Achieves a Historic Milestone: Blau Farmacêutica Fully Develops One of the World's Most Advanced Biosimilars Immunotherapies
PR Newswire —
With drug substance GMP approval from ANVISA and international regulatory progress, access to cancer immunotherapy in Brazil may be fundamentally transformed SÃO PAULO, Jan. 23, 2026 /PRNewswire/ -- Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market...